Buy or sell Thrive Earlier Detection stock pre IPO via an EquityZen fund
Thrive Earlier Detection Stock
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.
About Thrive Earlier Detection Stock
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences and Gamma3.
Chief Commercial Officer
David J. Daly
Chief People Officer
Chief Financial Officer